$224 Million is the total value of KPCB XV Associates, LLC's 4 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| UPST | Sell | Upstart Holdings, Inc. | $79,417,000 | -19.2% | 635,841 | -25.0% | 35.45% | -16.3% |
| TWLO | Buy | Twilio Inc. | $74,165,000 | +16.6% | 188,160 | +0.8% | 33.11% | +20.8% |
| RAPT | Sell | Rapt Therapeutics, Inc. | $41,234,000 | -4.6% | 1,297,063 | -33.4% | 18.41% | -1.2% |
| ATRA | Atara Biotherapeutics, Inc. | $29,182,000 | +8.3% | 1,876,650 | 0.0% | 13.03% | +12.2% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-07-28
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Twilio Inc. | 8 | Q3 2022 | 54.3% |
| Rapt Therapeutics, Inc. | 8 | Q3 2022 | 43.7% |
| Atara Biotherapeutics, Inc. | 8 | Q3 2022 | 27.0% |
| Upstart Holdings, Inc. | 3 | Q2 2021 | 42.4% |
| Augmedix, Inc. | 2 | Q2 2022 | 0.0% |
View KPCB XV Associates, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-10-26 |
| 13F-HR | 2022-07-21 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-10-25 |
| 13F-HR | 2021-07-28 |
| 13F-HR | 2021-05-13 |
| 13F-HR | 2021-02-16 |
| 4 | 2020-10-20 |
| 4 | 2020-09-11 |
View KPCB XV Associates, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.